Where does Carl Gordon work?

Carl Gordon is Managing Partner at OrbiMed and Board director at Belenos Biosciences and Board director at Alterome Therapeutics, Inc. and Board director at Odyssey Therapeutics.

What check size does Carl Gordon write?

Carl Gordon typically writes checks of $1M – $75M.

What boards does Carl Gordon sit on?

Carl Gordon holds tracked board seats at Adicet Bio, Belenos Biosciences, Compass Therapeutics, Gemini Therapeutics, Igenica Biotherapeutics, Keros Therapeutics, Prevail Therapeutics, SpringWorks Therapeutics, SpringWorks Therapeutics, Theseus Pharmaceuticals.

Where did Carl Gordon go to school?

Carl Gordon studied at Massachusetts Institute of Technology (Ph.D., Department of Biology); Harvard University (Bachelor's degree, Chemistry & Physics); Munster High School.

Carl Gordon

Investor

Managing Partner at OrbiMed · Board director at Belenos Biosciences · Board director at Alterome Therapeutics, Inc. · Board director at Odyssey Therapeutics

New York City Metropolitan Area

Writes $1M – $75M checks · typically $4M

Midas 2020 · #77 Midas 2019 · #14 Midas 2018 · #4 Midas 2017 · #8 Midas 2016 · #20 Midas 2015 · #89 Midas 2014 · #64

Find your path to Carl

583 people in our graph can introduce you to Carl.

Each arrow is one introduction. Sign up to fill in the first one.

Ask May Han to introduce you to Carl

You →May · together at The Rockefeller University (1993–1995) →Carl

Ask Jamie Chen to introduce you to Carl

You →Jamie · 11 people · together at OrbiMed →Carl

Your email: the people you already email who know Carl
2nd- and 3rd-degree connections: people you know who worked, studied or invested with Carl
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

About

Carl Gordon, an MIT Ph.D. and CFA with early hands‑on ImClone experience, is a founding GP and Co‑Head of global private equity repeatedly named to Forbes' Midas List and media‑shy.

Invests in

AI & Machine LearningBiotechHealthtechMedical Devices

Board director at Belenos Biosciences

Intro paths

→

In turn, Carl can intro founders to Belenos Biosciences's investors below.

Belenos Biosciences's investors · 1

OrbiMedNew York · $1M – $75M checks · since 2024

Co-founders at Belenos Biosciences

Donnie McGrathCEO & Co-Founder

Megan DowCOO & Co-Founder

Tania DimitrovaCFO & Co-Founder

Glenn RosenChief Translational Officer & Co-Founder

Donnie McGrath, M.D., M.P.H.CEO & Co-Founder

Megan Dow, Ph.D.COO & Co-Founder

Tania Dimitrova, M.B.ACFO & Co-Founder

Board director at Alterome Therapeutics, Inc.

Intro paths

→

In turn, Carl can intro founders to Alterome Therapeutics, Inc.'s investors below.

Alterome Therapeutics, Inc.'s investors · 6

Canaan PartnersStamford · $500K – $20M checks · since 2021 Digitalis VenturesNew York · $100K – $10M checks · since 2021 Nextech InvestZurich · $648K – $3.2M checks · since 2021 NVIDIASanta Clara · since 2021 OrbiMedNew York · $1M – $75M checks · since 2021 Vida VenturesLos Angeles · since 2021

Co-founders at Alterome Therapeutics, Inc.

Eric A. MurphyExecutive Officer, Director, Promoter

Board director at Odyssey Therapeutics

Intro paths

→

In turn, Carl can intro founders to Odyssey Therapeutics's investors below.

Odyssey Therapeutics's investors · 15

6 Dimensions CapitalGrand Cayman · since 2025 Activant CapitalNew York · $100K – $50M checks AlleyCorpNew York · $1M – $5M checks · since 2025 Ascenta CapitalWilmington · $15M – $30M checks · since 2023 Balderton CapitalLondon · $5M – $50M checks Catalio Capital Management, LPNew York Dimension CapitalSan Francisco · $1M – $10M checks · since 2025 Foresite CapitalWest Hollywood Global BioAccess FundNew York · $10M checks GreatPoint VenturesSan Francisco · $250K – $20M checks Jeito CapitalParis · since 2025 Lightspeed Venture PartnersMenlo Park · $1.7M – $87M checks OrbiMedNew York · $1M – $75M checks Sanofi VenturesCambridge · $5M checks SR One Capital ManagementRedwood City · since 2025

Co-founders at Odyssey Therapeutics

Gary D GlickExecutive Officer, Director

Experience

OrbiMed AdvisorsManaging Partnercurrent2018 — present
OrbiMed AdvisorsFounding General Partner1998 — 2018
Mehta and IsalyBiotechnology Analyst1995 — 1997New York
The Rockefeller UniversityPostdoctoral Fellow1993 — 1995New York
Imclone SystemsComputational Biology1987 — 1988New York

Deals · 7

Theseus PharmaceuticalsBoard seat

via OrbiMed · filed Feb 2021 · $22.1M raise

Compass TherapeuticsBoard seat

via OrbiMed · filed Jul 2020 · $195.3M raise

SpringWorks TherapeuticsBoard seat

via OrbiMed · filed Apr 2019 · $125M raise

Adicet BioBoard seat

via OrbiMed · filed Oct 2018 · $43.3M raise

Prevail TherapeuticsBoard seat

via OrbiMed · filed Mar 2018 · $65M raise

Gemini TherapeuticsBoard seat

via OrbiMed · filed May 2016 · $2M raise

Igenica BiotherapeuticsBoard seat

via OrbiMed · filed Jan 2015 · $6.3M raise

Attribution from SEC filings, press coverage, and firm rosters.

Other disclosed investments

Board seats

Belenos Biosciences Keros Therapeutics

Investor

Acadia PharmaceuticalsAcceleron PharmaADARx Pharmaceuticals Adimab Alector Alterome Therapeutics, Inc.Aragon Pharmaceuticals ArriventArsanisBlossomHill TherapeuticsComplete GenomicsCyrus BiotechnologyElectra Therapeutics Enyo PharmaFrontera TherapeuticsGood Start GeneticsIgenicaIntellia Therapeutics Kinnate Biopharma MBX Biosciences Odyssey Therapeutics Passage Bio RayThera Scribe TherapeuticsSelecta BiosciencesSeragon PharmaceuticalsSingulex Star Therapeutics Stratus TherapeuticsTurning Point TherapeuticsXinthera

Sources: SEC Form D filings · curated public sources.

Leave your own feedback

Colleagues at OrbiMed

Alexander M. Cooper

Investor at OrbiMed

Anat Nursella

Venture Partner at OrbiMed

Andrew P. Kanarek, CFA, CIPM

Venture Partner at OrbiMed

Network9

Peter ThielScout

Co-founder & Partner at Founders Fund

Liam RatcliffeScout

General Partner at New Leaf Venture Partners

Phil FerneauScout

Managing Partner at Borealis Ventures

Terry McGuireScout

Founding Partner at Polaris Partners

Beth Seidenberg

Founding Managing Director at Westlake Village BioPartners

Jason P. Hafler

Managing Director at Sanofi Ventures

Maha Katabi

General Partner at Sofinnova Ventures

Michael Rome

Managing Director at Foresite Capital

Mona Ashiya

General Partner at OrbiMed

Investors connected to Carl in public investor directories — a warm-intro map.

Frequently asked questions

Who is Carl Gordon?: Carl Gordon, an MIT Ph.D. and CFA with early hands‑on ImClone experience, is a founding GP and Co‑Head of global private equity repeatedly named to Forbes' Midas List and media‑shy.
Where does Carl Gordon work?: Carl Gordon is Managing Partner at OrbiMed and Board director at Belenos Biosciences and Board director at Alterome Therapeutics, Inc. and Board director at Odyssey Therapeutics.
What does Carl Gordon invest in?: Carl Gordon invests in AI & Machine Learning, Biotech, Healthtech, Medical Devices.
What check size does Carl Gordon write?: Carl Gordon typically writes checks of $1M – $75M.
What boards does Carl Gordon sit on?: Carl Gordon holds tracked board seats at Adicet Bio, Belenos Biosciences, Compass Therapeutics, Gemini Therapeutics, Igenica Biotherapeutics, Keros Therapeutics, Prevail Therapeutics, SpringWorks Therapeutics, SpringWorks Therapeutics, Theseus Pharmaceuticals.
What companies has Carl Gordon invested in?: Investments tracked here include Acadia Pharmaceuticals, Acceleron Pharma, ADARx Pharmaceuticals, Adimab, Alector, Alterome Therapeutics, Inc., Aragon Pharmaceuticals, Arrivent, Arsanis, BlossomHill Therapeutics, Compass Therapeutics, Complete Genomics, and 22 more.
Where did Carl Gordon go to school?: Carl Gordon studied at Massachusetts Institute of Technology (Ph.D., Department of Biology); Harvard University (Bachelor's degree, Chemistry & Physics); Munster High School.